Johnson & Johnson (NYSE:JNJ) The stock position was raised by Meridian Wealth Advisors LLC

VaselineSeptember 7, 2024

0 4 minutes read

Meridian Wealth Advisors LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.6% during the second quarter, HoldingsChannel.com reports. The fund owned 14,468 shares of the company’s stock after acquiring an additional 234 shares during the period. Meridian Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $2,115,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Inçalta Capital LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at approximately $27,000. Christopher J. Hasenberg Inc bought a new stake in Johnson & Johnson in the 1st quarter valued at $31,000. MFA Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $43,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at about $44,000. Finally, Grayhawk Investment Strategies Inc. raised its holdings in shares of Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the period. 69.55% of the shares are currently held by institutional investors and hedge funds.

Insiders place their bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the SEC, which is accessible via this link. Corporate insiders own 0.16% of the company’s shares.

Johnson & Johnson stock performance

Want more great investment ideas?

NYSE:JNJ opened at $164.41 on Friday. The company has a current ratio of 1.07, a quick ratio of 0.85, and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $157.57 and a 200-day moving average of $153.83. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The firm has a market cap of $395.68 billion, a price-to-earnings ratio of 10.25, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ – Get Free Report ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. In the same quarter last year, the business posted earnings of $2.80 per share. The company’s quarterly revenue was up 4.3% compared to the same quarter last year. analysts predict that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson announces dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, August 27. This represents a dividend of $4.96 on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analysts on Wall Street are forecasting an increase

JNJ has been the subject of several recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday. TD Securities reduced their price objective on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Goldman Sachs Group reduced their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Sanford C. Bernstein raised their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Moderate Buy” and an average target price of $173.21, according to MarketBeat.com.

Check out our latest analysis of JNJ

Johnson & Johnson profile

(Free report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.